- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02454309
Cranberry for the Prevention of Urinary Tract Infections
May 30, 2016 updated by: University of British Columbia
A Randomised, Double-blind, Placebo Controlled Trial Evaluating the Effectiveness of a Cranberry Concentrate (CranrichTM) in Preventing Recurrent Urinary Tract Infections in Adult Women
This study aims to determine whether a cranberry concentrate reduces recurrent urinary tract infections (UTIs) in women.
Approximately 150 adult women will be recruited to participate in this study.
Subjects will be randomized to either the cranberry supplement or placebo treatment for 12 months.
Subjects and investigators will be blinded to which supplement they are taking.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Participants will be randomized to receive either a cranberry concentrate or placebo.
Participants, study staff and investigators will remain blinded until after the dataset has been cleaned.
At the baseline visit participants will be instructed to consume the assigned supplement twice daily for 12 consecutive months.
A calendar will be provided to record compliance, recurrent UTIs and any side effects.
Participants will be phoned/texted each month to encourage participation.
Additional study visits will be completed at 3 months, 6 months and 9 months to collect information on recurrent UTIs and adherence.
A urine sample will be collected from participants at each visit to test for pregnancy and the presence of an undetected UTI.
Supplements will be distributed at each visit for the following 3-month study period and the last bottle of unused product returned.
At the 12-month visit, participants will complete an end-line questionnaire and return their supplement bottle in addition to the calendar and side effect diary.
If participants withdraw from the study, they will be encouraged to return at 12 months to complete a survey to allow for intent-to-treat analysis.
Study Type
Interventional
Enrollment (Anticipated)
150
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 1Z4
- Recruiting
- The University of British Columbia
-
Principal Investigator:
- Tim Green, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Females who have had at least 2 clinical-diagnosed symptomatic UTIs in the year preceding
- Can communicate in English
Exclusion Criteria:
- Current UTI
- Pregnant or breastfeeding or planning a pregnancy in the next 12 months
- known allergy or intolerance to cranberry-containing products
- A history of renal stones and/or renal transplantation
- Any immunosuppressive disease or other medical conditions that could potentially interfere with outcomes
- Current use of corticosteroid, anticoagulant, antidepressants or mood stabilizing medications or other medications that may interact with the supplement
- Intermittent or indwelling catheterization
- Any anatomic abnormalities of the urinary tract
- The use of any antibiotics within 2 weeks before study entry
- The use of any natural health products, including herbs, homeopathic products, or other forms of cranberry supplements within 2 weeks before study entry
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cranberry concentrate
Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate)
|
Other Names:
|
|
Placebo Comparator: Placebo
A capsule containing control formulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of urinary tract infections
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2015
Primary Completion (Anticipated)
December 1, 2016
Study Completion (Anticipated)
March 1, 2017
Study Registration Dates
First Submitted
May 22, 2015
First Submitted That Met QC Criteria
May 26, 2015
First Posted (Estimate)
May 27, 2015
Study Record Updates
Last Update Posted (Estimate)
June 1, 2016
Last Update Submitted That Met QC Criteria
May 30, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H15-00892
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Tract Infection
-
Gloucestershire Hospitals NHS Foundation TrustWithdrawnCatheter Infection | Urinary Tract Infection in Pregnancy | Urinary Tract Infection Following Delivery
-
Angela HUTTNERUniversity Hospital, GenevaEnrolling by invitationUrinary Tract Infection(UTI) | UTI - Urinary Tract Infection | Urinary Tract Infection, RecurrentSwitzerland, Netherlands, Germany
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedUrinary Tract Infection | Recurrent Urinary Tract InfectionCanada
-
Hadassah Medical OrganizationUnknown
-
Impatients N.V. trading as myTomorrowsInmunotek S.L.No longer availableUrinary Tract Infections | Bladder Infection | Recurrent Urinary Tract Infection | Urinary Tract Infection Bacterial | Chronic Urinary Tract InfectionCzechia, Denmark, Serbia, France, Germany, Turkey, Belgium, Finland, Luxembourg, Netherlands, Norway, Romania, Slovakia, Slovenia, Sweden
-
National Center for Complementary and Integrative...Office of Dietary Supplements (ODS)UnknownUrinary Tract InfectionCanada
-
National Institute of Allergy and Infectious Diseases...TerminatedUrinary Tract InfectionUnited States
-
University Of PerugiaUnknownUrinary Tract Infection
-
NanovibronixShaare Zedek Medical CenterUnknownUrinary Tract InfectionIsrael
-
Bactiguard ABRehab Station StockholmCompletedComplications; Catheter, Urinary Infection or InflammationSweden
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States